{
    "2019-02-19": [
        [
            {
                "time": "2018-04-20",
                "original_text": "恒瑞医药：业绩表现靓丽 研发投入再创新高",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "业绩",
                        "研发投入",
                        "创新高"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "恒瑞创新药阵营集齐“四大金刚”",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "创新药",
                        "四大金刚"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-20",
                "original_text": "【一图看财报】恒瑞医药：2018年净利同比增长26.39% 拟10送2派2.2元",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "净利增长",
                        "分红"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-19",
                "original_text": "明日最具投资机会六大牛股一览（2019年2月19日）",
                "features": {
                    "keywords": [
                        "投资机会",
                        "牛股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-05",
                "original_text": "60倍PE 12倍PB 15年长牛的药王恒瑞医药还能走多远？",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "PE",
                        "PB",
                        "长牛"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-15",
                "original_text": "大摩：医药股面对政策逆风 首选信达生物(01801.HK)等",
                "features": {
                    "keywords": [
                        "医药股",
                        "政策逆风",
                        "信达生物"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-02-25",
                "original_text": "【北上资金跟踪周报】陆股通延续放量净买入，偏好向成长股扩散",
                "features": {
                    "keywords": [
                        "北上资金",
                        "陆股通",
                        "净买入",
                        "成长股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-10",
                "original_text": "恒瑞医药:业绩优秀 创新药进入集中收获期",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "业绩优秀",
                        "创新药",
                        "收获期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-15",
                "original_text": "提前发布年报，恒瑞医药是在布局还是有苦衷？",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "年报",
                        "布局",
                        "苦衷"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-01-08",
                "original_text": "医药行业周报:国务院新年第一会任务部署 癌症、罕见病产业链将受益",
                "features": {
                    "keywords": [
                        "医药行业",
                        "国务院",
                        "癌症",
                        "罕见病",
                        "产业链"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}